Comparison 1. CESSATION OF CHLORPROMAZINE vs CONTINUATION OF CHLORPROMAZINE.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1. Not improved or worsened ‐ short term	1	95	Risk Ratio (M‐H, Fixed, 95% CI)	2.46 [1.51, 3.99]
2 Global state: 2. Relapse	9		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 short term	3	376	Risk Ratio (M‐H, Fixed, 95% CI)	6.76 [3.37, 13.54]
2.2 medium term	6	850	Risk Ratio (M‐H, Fixed, 95% CI)	4.04 [2.81, 5.81]
2.3 long term	3	510	Risk Ratio (M‐H, Fixed, 95% CI)	1.70 [1.44, 2.01]
3 Leaving study early ‐ any reasons ‐ medium term	1	374	Risk Difference (M‐H, Fixed, 95% CI)	0.01 [‐0.04, 0.06]
4 Mental state: Not improved or worsened	1	12	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.60, 1.66]
5 Sensitivity analysis: HIGH DOSE vs LOW DOSE ‐ outcome relapse	7		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 high dose (>500mg/day)	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 14.95]
5.2 low dose (<500mg/day)	6	934	Risk Ratio (M‐H, Fixed, 95% CI)	2.13 [1.79, 2.53]
6 Sensitivity analysis: DIAGNOSTIC CRITERIA vs NO‐DIAGNOSTIC CRITERIA ‐ outcome relapse	10		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 diagnostic criteria	1	374	Risk Ratio (M‐H, Fixed, 95% CI)	1.67 [1.42, 1.97]
6.2 no diagnostic criteria	9	637	Risk Ratio (M‐H, Fixed, 95% CI)	4.53 [2.83, 7.25]